£495.00

The 2023-2028 Outlook for Antipsychotic Drugs for Schizophrenia in Japan

Subjects

Price data last checked 23 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 68 days · 68 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 68 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (68 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 68 days

Description

This study covers the latent demand outlook for antipsychotic drugs for schizophrenia across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for antipsychotic drugs for schizophrenia. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of antipsychotic drugs for schizophrenia as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BP9P1VTF
Category: Books > Subjects
Domain: Amazon UK
Release Date: 28 November 2022
Listed Since: 08 December 2022

The 2023-2028 Outlook for Antipsychotic Drugs for Schizophrenia in Japan

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for First Generation Antipsychotic Drugs for Schizophrenia in Japan

The 2023-2028 Outlook for Schizophrenia Drugs in Japan

The 2023-2028 Outlook for Schizophrenia Therapeutics in Japan

The 2023-2028 Outlook for Schizophrenia Treatments in Japan

The 2023-2028 Outlook for Antipsychotic Drugs for Schizophrenia in the United States

The 2023-2028 Outlook for First Generation Antipsychotic Drugs for Schizophrenia for US Zip Codes

The 2023-2028 Outlook for Schizophrenia Drugs in the United States

The 2023-2028 Outlook for Schizophrenia Treatments in the United States

The 2025-2030 World Outlook for Psychiatric and Substance Abuse Hospitals

Schizophrenia: Effects on Daily Life (DVD) (Concept Media: Educational Videos)

Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework: 63 (Current Topics in Behavioral Neurosciences, 63)

Schizophrenie: Dopaminrezeptoren und Neuroleptika

Schizophrenia Treatment - The New Facets

Schizophrenia: An Integrated View Albert Benzon Symposium 38: v. 38 (Alfred Benzon Symposium Series)

Schizophrenia in the 21st Century

Schizophrenie:: Interaktionsprozesse Und Emotionales Klima in Der Familie: 308 (Europaeische Hochschulschriften / European University Studie)

Psychotherapy of Preoedipal Conditions: Schizophrenia and Severe Character Disorders: Schizophrenia and Severe Character Disorders

New Approaches to the Management and Diagnosis of Schizophrenia

A Phenomenological Interpretation of Schizophrenia: Subjectivation, Framework and Perspective

Schizophrenia: A Contemporary Introduction (Routledge Introductions to Contemporary Psychoanalysis)

Neuroproteomics as a Tool for Understanding Schizophrenia: 1400 (Advances in Experimental Medicine and Biology, 1400)

Novel Antischizophrenia Treatments: 213 (Handbook of Experimental Pharmacology, 213)

Psychotropic Drugs in Psychiatry (Psychotropic Drugs in Psychiatry C)

Nova Science Self Fragmentation and Self Integration Schizophrenia